1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

What’s Next? Five Things To Look Out For In June

First Ophthalmic Biosimilar To Launch In US; Alvotech Merger To Close

 
• By Dean Rudge

In June, Medicines for Europe will host its annual and legal affairs conferences in Barcelona, while on the commercial side Hikma’s CEO Siggi Olafsson is to resign from the London-listed company.

What's Next Image
June is a busy month for industry • Source: Informa

History is to be made in June with the launch of the first biosimilar anti-VEGF product for ophthalmic conditions in the US: Samsung Bioepis’ Byooviz (ranibizumab-nuna) referencing Genentech’s Lucentis (ranibizumab) blockbuster. (Also see "FDA Approves First Ophthalmic Biosimilar With Samsung Bioepis’ Lucentis Rival" - Generics Bulletin, 20 September, 2021.)

Approved by the FDA in September last year, Byooviz had been expected to begin shipping in the US by the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products